John S Davies

14PUBLICATIONS
53CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)AllergyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Infectious agents
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Sep 10, 2026
Unphosphorylated tyrosines mediate PD-1 inhibition of T cell signaling condensate formation.

|Apr 09, 2025
CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses.

Kilyna A Nguyen, Zhihui Liu, John S Davies

|Nov 18, 2024
Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants.

Ling Zhang, Scott M Norberg, Farrah Karimipour

|Jun 10, 2024
Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege.

David Rutkowski, Rachel Scholey, John Davies

|Mar 15, 2024
Preclinical and translational pharmacology of afucosylated anti-CCR8 antibody for depletion of tumour-infiltrating regulatory T cells.

Gautham Gampa, Phillip Spinosa, Jennifer Getz

|Nov 09, 2023
CD3ζ ITAMs enable ligand discrimination and antagonism by inhibiting TCR signaling in response to low-affinity peptides.

Guillaume Gaud, Sooraj Achar, François X P Bourassa

Pageof 3

Frequent Collaborators

4 joint publications

Sooraj R Achar

4 joint publications

Naomi Taylor

4 joint publications

Christian S Hinrichs

4 joint publications

Grégoire Altan-Bonnet